Anika Therapeutics (ANIK) EBIAT (2016 - 2025)
Historic EBIAT for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to -$3.2 million.
- Anika Therapeutics' EBIAT rose 8938.77% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.6 million, marking a year-over-year increase of 6543.07%. This contributed to the annual value of -$56.4 million for FY2024, which is 3179.26% up from last year.
- Latest data reveals that Anika Therapeutics reported EBIAT of -$3.2 million as of Q3 2025, which was up 8938.77% from -$4.6 million recorded in Q2 2025.
- Anika Therapeutics' EBIAT's 5-year high stood at $6.5 million during Q2 2021, with a 5-year trough of -$63.0 million in Q4 2023.
- In the last 5 years, Anika Therapeutics' EBIAT had a median value of -$4.5 million in 2024 and averaged -$8.7 million.
- In the last 5 years, Anika Therapeutics' EBIAT skyrocketed by 18473.02% in 2021 and then crashed by 118361.86% in 2023.
- Anika Therapeutics' EBIAT (Quarter) stood at -$5.8 million in 2021, then grew by 15.28% to -$4.9 million in 2022, then tumbled by 1183.62% to -$63.0 million in 2023, then surged by 65.29% to -$21.9 million in 2024, then skyrocketed by 85.48% to -$3.2 million in 2025.
- Its EBIAT stands at -$3.2 million for Q3 2025, versus -$4.6 million for Q2 2025 and -$4.9 million for Q1 2025.